🧬Amended Meeting Notice for National Human Genome Research Institute
The notice announces a change in the meeting schedule for the National Advisory Council for Human Genome Research from a two-day to a one-day format. The meeting will now take place in person and virtually, allowing for broader attendance and participation. The notice includes the adjusted timing and a link for virtual attendance.
Learn More❌Notice of Cancellation for NIH Meeting in June 2025
The Department of Health and Human Services issues a notice regarding the cancellation of the Center for Scientific Review Special Emphasis Panel meeting scheduled from June 2-4, 2025. This amendment informs stakeholders about the change in the meeting schedule that was initially published earlier in the Federal Register.
Learn More📅Notice of Amended Meeting for NIH Scientific Review Panel
The document provides an amended notice regarding the meeting schedule of the NIH Center for Scientific Review Special Emphasis Panel focusing on neurodegeneration and brain injury. The notice includes updated contact information for the panel's review officer and emphasizes that the meeting is closed to the public.
Learn More📅Notice of Change in National Heart, Lung, and Blood Advisory Council Meeting Schedule
The Department of Health and Human Services announces a change in the meeting schedule of the National Heart, Lung, and Blood Advisory Council. The meeting is partially closed to the public and will occur on June 11, 2025, at the Porter Neuroscience Research Center in Bethesda, MD.
Learn More💰NIH Announces Closed Meetings for Grant Evaluations
The Department of Health and Human Services announces several closed meetings by the National Institutes of Health to evaluate grant applications. These meetings pertain to specific panels focused on scientific research topics, ensuring confidentiality and the protection of sensitive information while facilitating assessments that influence research funding.
Learn More🏥Amended Meeting Notice from the National Heart, Lung, and Blood Institute
The notice provides updates on the rescheduling of the National Heart, Lung, and Blood Advisory Council meeting. It specifies the new start and end times and indicates that the meeting will partially be closed to the public, while referencing a prior publication in the Federal Register.
Learn More📊Request for Public Comments on SRAE Data Collection Initiative
The Administration for Children and Families' (ACF) Office of Planning, Research, and Evaluation (OPRE) requests Office of Management and Budget (OMB) approval for an overarching generic clearance to collect data from programs delivered by Sexual Risk Avoidance Education (SRAE) grant recipients on behalf of the SRAE National Evaluation. The generic mechanism will allow ACF to rapidly respond to research and evaluation opportunities that would not otherwise be feasible under the timelines associated with the Paperwork Reduction Act of 1995. The opportunities may relate to innovative implementation strategies and program components in use by SRAE grant recipients as they arise, and in particular, for youth subpopulations served by grant recipients. The purpose of the data collections submitted under the generic will be to inform ACF programming by building evidence about what innovations work to improve programming and outcomes across the SRAE grant recipients and the youth they serve.
Learn More💊Exclusive Patent License for CNS Therapeutics by NIH
The National Institute of Neurological Disorders and Stroke and the National Center for Advancing Translational Sciences, institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Psycala Bio, Inc. (Psycala), incorporated in Delaware.
Learn More🚫FDA Debarment Order
The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Justin Cole Henry for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Henry was convicted of a felony under Federal law for possession with intent to distribute a Schedule III controlled substance. The factual basis supporting Mr. Henry's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Henry was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of February 24, 2025 (30 days after receipt of the notice), Mr. Henry had not responded. Mr. Henry's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.
Learn More💰NIH Grant Review Meetings for Small Businesses in June 2025
The Department of Health and Human Services announces closed meetings where the Center for Scientific Review will evaluate various grant applications. These meetings focus on significant healthcare topics and grant opportunities aimed at advancing research and development in the biomedical field.
Learn More